A switch from current HMG CoA reductase inhibitor [statin] therapy to either cerivastatin 0.4 or 0.8 mg/day or simvastatin 80 mg/day

By  

Inpharma, Vol. 1, Iss. 1307, 2001-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

EFFECT OF THE NEW HMG-CoA REDUCTASE INHIBITOR CERIVASTATIN (BAY W 6228) ON MIGRATION, PROLIFERATION AND CHOLESTEROL SYNTHESIS IN ARTERIAL MYOCYTES

By Corsini A.   Arnaboldi L.   Raiteri M.   Quarato P.   Faggiotto A.   Paoletti R.   Fumagalli R.  

Pharmacological Research, Vol. 33, Iss. 1, 1996-01 ,pp. : 55-61

Academic Press

Access to resources Recommend Favorite

HMG CoA reductase inhibitor therapy underused after CAGB

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 364, 2002-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

HMG CoA reductase inhibitor [statin] therapy should be considered for older patients

By  

Inpharma, Vol. 1, Iss. 1237, 2000-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

The HMG CoA reductase inhibitor [statin] atorvastatin [`Lipitor'; Pfizer], has garnered a Q3 sales increase

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 339, 2001-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite